About BlueRock Therapeutics
BlueRock Therapeutics news and updates
Versant Ventures invested into BlueRock Therapeutics in $225M on Jan 1st 16'.
BlueRock was founded in 2016 with $225 million in Series A financing from Bayer and Versant Ventures.
Jan 1, 2019 | pitchbook.comBayer Inc. acquires BlueRock Therapeutics
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a propri ... more
Jan 1, 2022 | bionity.comBlueRock Therapeutics partners with Opsis Therapeutics, LLC.
BlueRock is teaming up with Opsis Therapeutics, a biotech that develops cell replacement therapies for the eyes, and Fujifilm Cellular Dynamics, a developer and manufacturer of induced pluripotent stem cells (iPSCs), cells that can be developed into any type of human cell for use in cell therapies.
Jan 1, 2021 | medcitynews.comBlueRock Therapeutics partners with BioCardia, Inc.
(iStock / Getty Images Plus) Bayer’s BlueRock Therapeutics has partnered with BioCardia on the delivery of cell therapies, paying a “sizable” upfront fee to access minimally invasive technology that could get its heart failure candidates to their targets.
Aug 30, 2022 | fiercepharma.comBlueRock Therapeutics is developing cell therapies for eye diseases on May 1st 21'.
In May 2021, BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics joined forces to research and develop cell therapies for eye diseases.
Sep 28, 2022 | icrowdnewswire.com